Roy Katzin, MD
Neurology · Boca Raton, FLNPI 1801987748
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Catalyst Pharmaceuticals, Inc. at 55.9% of the total. Reporting peaked in 2019 at $4,122 and has fallen 99.1% since, to $37 in 2025.
Across 116 payments — averaging $42.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catalyst Pharmaceuticals, Inc.$3K
- EMD Serono, Inc.$205
- Abbott$203
- Amgen$175
- Biogen$147
- Eisai Inc.$125
- plus $1K from 32 others
What the payments were for
- Speaking & faculty fees$2,54952%
- Travel & lodging$601%
- Food & beverage$2,29747%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | 3 | $2,752 |
| EMD Serono, Inc. | 14 | $205 |
| Abbott | 4 | $203 |
| Amgen | 8 | $175 |
| Biogen | 9 | $147 |
| Eisai Inc. | 6 | $125 |
| Acadia Pharmaceuticals Inc | 7 | $103 |
| Johnson & Johnson | 4 | $95 |
| UCB, Inc. | 4 | $83 |
| Merz North America, Inc. | 3 | $71 |
| Genentech USA, Inc. | 4 | $65 |
| MDD US Operations, LLC | 4 | $64 |
| Novartis | 4 | $62 |
| AbbVie(2 entities) | 3 | $60 |
| Zimmer Biomet | 3 | $57 |
| Integra Lifesciences Corporation | 2 | $54 |
| Sanofi | 3 | $54 |
| Lilly USA, LLC | 3 | $51 |
| Acorda Therapeutics, Inc | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| AstraZeneca | 2 | $41 |
| Livanova USA, Inc. | 2 | $33 |
| Neurelis, Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| SK Life Science, Inc. | 1 | $26 |
| CSL Behring | 1 | $23 |
| Aprecia Pharmaceuticals, LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Aquestive Therapeutics, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,920 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Boca Raton
- Stuart IsaacsonBoca Raton$3.9M
- Brian SteingoBoca Raton$792K
- Richard IsaacsonBoca Raton$127K
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.